Ember LifeSciences Expands Series A to $27 Million with Amgen Ventures and TDF Ventures

May 27, 2026
Ember LifeSciences has added new strategic investments from Amgen Ventures and TDF Ventures, bringing its Series A funding total to $27 million. The company also announced the commercial launch of the Ember Cube 2, a reusable cold chain shipping solution with real-time monitoring and cloud tracking.

Ember LifeSciences has received new strategic investments from Amgen Ventures, the corporate venture arm of Amgen, and TDF Ventures, announced in a press release. The new backing raises Ember's total Series A funding to $27 million, following an earlier round led by Sea Court Capital.

The funding coincides with the full commercial release of the Ember Cube 2, a reusable and modular cold chain shipping solution designed for temperature sensitive pharmaceuticals. The system offers real time monitoring and cloud based tracking to improve control and visibility across logistics operations.

Ember LifeSciences, a spinout from Ember Technologies, focuses on temperature control technology for medicine and vaccine transport. The Ember Cube 2 was recently recognized with the Red Dot Award for product design, while the original Ember Cube was named a 2024 TIME Magazine Invention of the Year and a Fast Company World Changing Idea.

Existing customers and investors include CVS Health, Cardinal Health, Chartwell, and USADA. Financial details of the latest investments were not disclosed.

We hope you enjoyed this article

Free newsletter

AI Funding Brief

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.